GLP-1 Semaglutide Programme

Doctor-prescribed semaglutide (Ozempic, WeGovy) and oral Rybelsus programmes for metabolic health and sustainable weight loss, with clinical monitoring and dose titration managed by the Bay Aesthetics medical team throughout the treatment course.

Bay Aesthetics Clinic MediSpa's GLP-1 semaglutide programme provides access to the latest generation of metabolic and weight-management medications under the direct supervision of Dr Bernard Tan and the clinic's medical team. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the body's natural satiety hormone, reducing appetite, slowing gastric emptying and regulating blood glucose — producing sustained weight loss that is difficult to achieve through diet and exercise alone. The weekly injectable formulations — Ozempic (approved for type 2 diabetes management) and WeGovy (approved for chronic weight management) — are administered via a small subcutaneous pen injection once weekly, making them convenient for busy professionals. The dose is titrated gradually over the initial weeks (starting at 0.25mg weekly) to minimise gastrointestinal side effects such as nausea, vomiting and bloating, which typically diminish as the body adjusts. For patients who prefer oral medication, Rybelsus (oral semaglutide 3mg, 7mg or 14mg) is taken once daily on an empty stomach at least 30 minutes before food or other medications. While oral bioavailability is lower than the injectable form, Rybelsus provides meaningful improvements in blood glucose control and modest weight reduction for patients with mild-to-moderate metabolic concerns. Clinical trial data from the STEP programme demonstrated that high-dose semaglutide (2.4mg weekly) combined with lifestyle intervention achieves average weight loss of 15–17% of body weight over 68 weeks — a result previously achievable only with bariatric surgery. At Bay Aesthetics, the programme is paired with nutritional guidance and, optionally, body-sculpting treatments to optimise physical results as weight reduces. The clinic conducts baseline blood tests, BMI measurement and a full medical history review before prescribing. Ongoing monitoring of metabolic markers ensures the programme is both effective and safe for each patient.